CDI-988 is a direct-acting, oral antiviral being developed for norovirusNorovirus challenge study is underway at Emory ...

This time of year is prime season for these fast-spreading illnesses.

CDI‑988 is the first oral antiviral drug candidate being developed for prevention and treatment of norovirus infectionsCompany to present Phase 1 data and updates from ongoing Phase 1b study conducted ...

“Norovirus can mutate easily, similar to other viruses like influenza and Covid,” says Lucy Thorne, a lecturer in molecular ...

The two share many symptoms, but timing and severity can reveal what’s really behind your sickness ...

Subject enrollment expected to begin in Q1 2026 CDI-988 is the first oral broad-spectrum antiviral drug candidate for potential prevention of norovirus outbreaks and treatment of acute viral ...

Cocrystal Pharma, Inc. announced that its investigational antiviral drug CDI-988 has shown strong efficacy against the newly dominant norovirus variants GII.17 and previously prevalent GII.4, amid a ...

There are currently no approved vaccines or treatments for norovirus infection Cocrystal’s CDI-988 is the first antiviral for the potential prevention and treatment of viral gastroenteritis caused by ...

A fast-moving virus is spreading across North Carolina, slipping from person to person - and there's no treatment to stop it. From Aug. 1-Nov. 13, there were 153 norovirus outbreaks reported in 14 ...

A ward is shut and cleaning regimes are stepped up to clamp down on the winter vomiting bug.

The Food and Drug Administration is advising restaurants and food retailers not to serve or sell and to dispose of, and consumers not to eat certain raw oysters and Manila clams harvested in ...